Myeloma Investment Fund Invests in Nectin Therapeutics to Evaluate Nectin’s Anti-PVR Lead Drug Candidate as a Treatment for Multiple Myeloma
Previous
Previous
Cancer Focus Fund Investing $4.5 Million in ImmunoGenesis to Support Drug Trial for Relapsed or Refractory Advanced Solid Tumors
Next
Next